Rapid and continuous accumulation of nitric oxide-releasing liposomes in tumors to augment the enhanced permeability and retention (EPR) effect

Takuma Yoshikawa, Yukina Mori, Haitao Feng, Khanh Quoc Phan, Akihiro Kishimura, Jeong Hun Kang, Takeshi Mori, Yoshiki Katayama

Research output: Contribution to journalArticle

Abstract

The modulation of blood flow to tumors is a prominent strategy for improving the tumor accumulation of nanomedicines, resulting from the enhanced permeability and retention (EPR) effect. We previously reported a promising EPR enhancer—a nitric oxide (NO) donor-containing liposome (NO-LP)—which showed enhanced accumulation in tumor tissue. Herein, we study NO-LP in greater detail to clarify its practical use as an EPR enhancer. NO-LP was found to have advantages as a NO donor, including the ability to maintain NO donation over long periods of time, and a constant rate of NO-release irrespective of the environmental pH. NO-LP showed rapid accumulation in tumor tissue after injection (1 h), and then accumulation was continuously enhanced until 48 h. Enhanced NO-LP accumulation was observed specifically in tumor, while the accumulation in other organs remained relatively unchanged. The results obtained show the promising features of NO-LP as an EPR enhancer.

Original languageEnglish
Pages (from-to)481-487
Number of pages7
JournalInternational Journal of Pharmaceutics
Volume565
DOIs
Publication statusPublished - Jun 30 2019

Fingerprint

Liposomes
Permeability
Nitric Oxide
Neoplasms
Nitric Oxide Donors
Nanomedicine
Injections

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Rapid and continuous accumulation of nitric oxide-releasing liposomes in tumors to augment the enhanced permeability and retention (EPR) effect. / Yoshikawa, Takuma; Mori, Yukina; Feng, Haitao; Phan, Khanh Quoc; Kishimura, Akihiro; Kang, Jeong Hun; Mori, Takeshi; Katayama, Yoshiki.

In: International Journal of Pharmaceutics, Vol. 565, 30.06.2019, p. 481-487.

Research output: Contribution to journalArticle

@article{415912673a3740c9935ddaaab5af5b48,
title = "Rapid and continuous accumulation of nitric oxide-releasing liposomes in tumors to augment the enhanced permeability and retention (EPR) effect",
abstract = "The modulation of blood flow to tumors is a prominent strategy for improving the tumor accumulation of nanomedicines, resulting from the enhanced permeability and retention (EPR) effect. We previously reported a promising EPR enhancer—a nitric oxide (NO) donor-containing liposome (NO-LP)—which showed enhanced accumulation in tumor tissue. Herein, we study NO-LP in greater detail to clarify its practical use as an EPR enhancer. NO-LP was found to have advantages as a NO donor, including the ability to maintain NO donation over long periods of time, and a constant rate of NO-release irrespective of the environmental pH. NO-LP showed rapid accumulation in tumor tissue after injection (1 h), and then accumulation was continuously enhanced until 48 h. Enhanced NO-LP accumulation was observed specifically in tumor, while the accumulation in other organs remained relatively unchanged. The results obtained show the promising features of NO-LP as an EPR enhancer.",
author = "Takuma Yoshikawa and Yukina Mori and Haitao Feng and Phan, {Khanh Quoc} and Akihiro Kishimura and Kang, {Jeong Hun} and Takeshi Mori and Yoshiki Katayama",
year = "2019",
month = "6",
day = "30",
doi = "10.1016/j.ijpharm.2019.05.043",
language = "English",
volume = "565",
pages = "481--487",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",

}

TY - JOUR

T1 - Rapid and continuous accumulation of nitric oxide-releasing liposomes in tumors to augment the enhanced permeability and retention (EPR) effect

AU - Yoshikawa, Takuma

AU - Mori, Yukina

AU - Feng, Haitao

AU - Phan, Khanh Quoc

AU - Kishimura, Akihiro

AU - Kang, Jeong Hun

AU - Mori, Takeshi

AU - Katayama, Yoshiki

PY - 2019/6/30

Y1 - 2019/6/30

N2 - The modulation of blood flow to tumors is a prominent strategy for improving the tumor accumulation of nanomedicines, resulting from the enhanced permeability and retention (EPR) effect. We previously reported a promising EPR enhancer—a nitric oxide (NO) donor-containing liposome (NO-LP)—which showed enhanced accumulation in tumor tissue. Herein, we study NO-LP in greater detail to clarify its practical use as an EPR enhancer. NO-LP was found to have advantages as a NO donor, including the ability to maintain NO donation over long periods of time, and a constant rate of NO-release irrespective of the environmental pH. NO-LP showed rapid accumulation in tumor tissue after injection (1 h), and then accumulation was continuously enhanced until 48 h. Enhanced NO-LP accumulation was observed specifically in tumor, while the accumulation in other organs remained relatively unchanged. The results obtained show the promising features of NO-LP as an EPR enhancer.

AB - The modulation of blood flow to tumors is a prominent strategy for improving the tumor accumulation of nanomedicines, resulting from the enhanced permeability and retention (EPR) effect. We previously reported a promising EPR enhancer—a nitric oxide (NO) donor-containing liposome (NO-LP)—which showed enhanced accumulation in tumor tissue. Herein, we study NO-LP in greater detail to clarify its practical use as an EPR enhancer. NO-LP was found to have advantages as a NO donor, including the ability to maintain NO donation over long periods of time, and a constant rate of NO-release irrespective of the environmental pH. NO-LP showed rapid accumulation in tumor tissue after injection (1 h), and then accumulation was continuously enhanced until 48 h. Enhanced NO-LP accumulation was observed specifically in tumor, while the accumulation in other organs remained relatively unchanged. The results obtained show the promising features of NO-LP as an EPR enhancer.

UR - http://www.scopus.com/inward/record.url?scp=85065717913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065717913&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2019.05.043

DO - 10.1016/j.ijpharm.2019.05.043

M3 - Article

VL - 565

SP - 481

EP - 487

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

ER -